Janux Therapeutics JANX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$24.36M-3.6% | -$31.95M-58.0% | -$24.31M+13.4% | -$33.86M-468% | -$23.51M-59.3% | ||
| $469K-9.6% | $468K-8.6% | $501K-1.8% | $541K+6.9% | $519K-2.4% | ||
| $9.27M-13.4% | $9.52M+52.2% | $9.04M-41.2% | $10.96M+90.4% | $10.7M+90.3% | ||
| $35M— | —— | —— | $0-100% | $0-100% | ||
| -$1.61M+1.5% | $1.67M+7.1% | -$168K-114% | $1.11M+260% | -$1.64M-259% | ||
| -$2.03M-217% | —— | $6.18M+35.1% | $2.89M-5.5% | $1.73M+210% | ||
| $1.34M+1,552% | -$19K-131% | -$66K-136% | -$99K-185% | -$92K-713% | ||
| $46.27M— | $0— | $0+100% | $0+100% | $0+100% | ||
| -$12.34M+27.5% | -$28.54M-70.7% | -$12.86M-476% | -$23.81M-138% | -$17.02M-14.7% | ||
| $273K-26.4% | $106K+152% | $93K+272% | $473K+398% | $371K+88.3% | ||
| $112.75M-69.6% | $123.28M+413% | $117.97M+263% | $92.69M-60.6% | $371.29M+108% | ||
| $121.31M+288% | $152.93M+164% | $126.37M+180% | $94.72M+112% | $31.27M-51.9% | ||
| $8.29M+102% | —— | —— | —— | -$340.39M-199% | ||
| $3.55M+293% | —— | —— | —— | $901K-45.6% | ||
| $3.55M+540% | $2.94M-99.2% | $493K-70.1% | $954K-65.5% | $554K-99.8% | ||
| -$506K+99.9% | $0-100% | -$4.06M-134% | -$21.3M+89.3% | -$356.86M-284% | ||
| $2.62M-37.8% | $3.52M+20.4% | $4.62M+59.5% | $5.21M+75.1% | $4.22M+136% | ||
| $469K-9.6% | $468K-8.6% | $501K-1.8% | $541K+6.9% | $519K-2.4% | ||
| $46.27M— | $0— | $0+100% | $0+100% | $0+100% | ||
| $36K+620% | —— | —— | $6K+132% | $5K+125% | ||
| $1.34M+91.9% | $227K+11.8% | —— | $349K-80.2% | $700K-40.2% | ||
| $121.31M+288% | $152.93M+164% | $126.37M+180% | $94.72M+112% | $31.27M-51.9% | ||
| $0-100% | —— | —— | —— | $347K— | ||
| $25K-89.5% | -$101K— | $54K+28.6% | -$190K— | $237K— | ||
| -$3.74M-335% | —— | $815K-91.4% | -$9K+99.2% | $1.59M+234% | ||
| —— | $235.75K— | $235.75K— | $235.75K— | $235.75K— | ||
| -$12.61M+27.5% | -$28.65M-70.9% | -$12.95M-474% | -$24.29M-140% | -$17.4M-15.7% | ||
| -$12.61M+27.5% | -$28.65M-70.9% | -$12.95M-474% | -$24.29M-140% | -$17.4M-15.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Janux Therapeutics generate?
- Janux Therapeutics (JANX) generated -$77.5M in operating cash flow over the trailing twelve months.
- What is Janux Therapeutics's free cash flow?
- After $945.0K of capital expenditures, Janux Therapeutics's free cash flow was -$78.5M over the trailing twelve months, down 68.7% year over year.
- Where does Janux Therapeutics's cash flow data come from?
- Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
